Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

• click to rate

  Posted by Two Blokes Jun 27 - Filed in Stock - 4 views
  
  On Thursday, Altimmune, Inc. ALT released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).